Julia TCW’s lab focuses on developing Alzheimer’s disease (AD) therapeutics using human induced pluripotent stem cells (iPSCs) and genetic methods. The work has three main goals: identifying genes in brain cells affected by AD, studying AD genetic mechanisms using iPSCs and mouse models, and creating human brain models for drug screening.

In collaboration with the Functional Genomics Consortium (xQTL study) in Alzhiemer's Disease Sequencing Project, the lab analyzes large-scale genetic, epigenetic and multi-omics data to uncover variants linked to methylation, histone modification, multi-omics changes in the brain. They focus on understanding how AD genetic risks, especially APOE4, impact brain cells by using advanced computational and experimental techniques. The lab develops novel tools to integrate genetics, transcriptomics, and proteomics data to explore AD molecular pathways. They also collaborate with industry to find new drug targets, advancing both 2D and 3D brain cell models for drug discovery.